1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Stereotaxis completed its acquisition of Robocath, a French medical device company, on July 7, 2026, and filed supplemental risk factors. The filing says the deal will not be accretive and will increase Stereotaxis's operating losses in the near term, and that issuing shares for the earnout could dilute existing stockholders.
Stereotaxis issued 6,269,628 closing shares at the July 7, 2026 closing, including 225,000 shares paid to Robocath's financial advisor.
The Share Sale Agreement allows up to $25 million of earnout consideration, payable in cash, shares, or both, if regulatory and commercial milestones are met.
Stereotaxis registered 13,179,975 possible earnout shares, with a cap of 19.9% of shares outstanding as of July 7, 2026, including the closing shares.
Stereotaxis extended $1.1 million in operating loans to Robocath before closing; the loans were repaid at closing and reduced the upfront stock consideration.
The Hanover Insurance Group said CEO John C. Roche will retire as president, CEO and board member effective December 31, 2026. Chief Operating Officer Richard W. Lavey has been named CEO-elect and is expected to succeed Roche as CEO at that time, with a board seat from January 1, 2027. The filing reports no financial results, but it changes the company's top executive role.
John C. Roche, 62, retires as president, CEO and board member effective December 31, 2026, and stays as an advisor through January 8, 2027.
Richard W. Lavey, 59, has been Executive Vice President and Chief Operating Officer since March 2025 and is named CEO-elect.
The Board intends to elect Lavey to the Board effective January 1, 2027.
The company's earnings call is scheduled for July 29, 2026, and its investor day for September 17, 2026.
Creative Media & Community Trust received a default notice on July 9, 2026 for the non-recourse mortgage on 1 Kaiser Plaza, which matured July 1, 2026. The company said it chose not to invest additional capital needed to refinance, and the lender has demanded immediate repayment and is collecting property rents, so shareholders face possible loss of this asset and uncertain resolution terms.
Notice of maturity default received July 9, 2026 on the 1 Kaiser Plaza mortgage, which matured July 1, 2026
Aggregate outstanding principal balance of the loan is $97.1 million as of the filing date
Lender has demanded immediate payment in full; property rents are now held for the lender and default interest may apply
Company remains current on monthly interest payments and is evaluating options, with no assurance on timing or outcome
RxSight's board appointed Aziz Mottiwala as President and Chief Executive Officer on July 13, 2026, effective July 20, 2026, replacing Ron Kurtz, M.D., who has led the company since 2016. Kurtz moves to Chief Medical Officer and resigns from the board, and Mottiwala joins the board in his place. The company said it is not updating its previously communicated financial guidance.
Mottiwala, 48, was Chief Commercial Officer of Tarsus Pharmaceuticals from August 2020 to July 2026.
Mottiwala's pay includes a $750,000 base salary, a 2026 cash bonus of $337,500, and equity awards with a grant-date value of $14,000,000.
Kurtz keeps a $740,000 base salary and can earn retention bonuses of $370,000 on each of four dates from January 1, 2027 through July 1, 2028, if he remains employed.
The company is not updating its previously communicated financial guidance in connection with the announcement.
On July 12, 2026, First Hawaiian, Inc. signed a merger agreement with TriCo Bancshares, under which TriCo will merge into a First Hawaiian subsidiary and then into First Hawaiian, followed by a bank merger of Tri Counties Bank into First Hawaiian Bank. TriCo shareholders will receive 2.095 First Hawaiian shares for each TriCo share, so the deal would dilute existing First Hawaiian shareholders and depends on shareholder, regulatory and registration approvals.
Exchange ratio: each TriCo common share converts into 2.095 First Hawaiian common shares, with cash paid in lieu of fractional shares
Termination fee of $80 million payable by either party in certain circumstances
Four TriCo directors will join the First Hawaiian board at the effective time
Closing requires stockholder and shareholder approvals, Federal Reserve, FDIC and state regulatory approvals, and effectiveness of a Form S-4 registration statement
Martin Marietta entered a $1.5 billion three-year senior unsecured term loan on July 15, 2026, and amended its $800 million revolving credit facility on July 10, 2026. Both are tied to its previously announced acquisition of Lhoist North America, with the term loan's proceeds usable to pay part of the cash consideration. The filing sets a maximum leverage ratio that steps down after the deal closes, which shows the debt load the company will carry.
Term Facility: $1,500,000,000 three-year senior unsecured term loan with JPMorgan Chase Bank, N.A. as administrative agent, available subject to the Lhoist North America acquisition closing
Revolving facility amendment dated July 10, 2026 sets maximum leverage ratio of 4.75:1.00 for the first three fiscal quarters after closing, 4.25:1.00 for the next three, and 3.75:1.00 thereafter
Commitment fee on undrawn term loan commitments begins October 25, 2026
United Airlines Holdings reported second-quarter 2026 results, with total operating revenue of $17.7 billion, up 16.0% from a year earlier, and diluted earnings per share of $2.46 (adjusted $1.99). It raised its full-year 2026 adjusted diluted EPS guidance to $9.00-$11.00, but expects nearly $6 billion in added fuel expense for the year versus its January expectation, which is the main cost pressure for shareholders.
Q2 2026 total operating revenue $17.7 billion, up 16.0%; net income $805 million; pre-tax earnings $1.0 billion
Full-year 2026 adjusted diluted EPS guidance raised to $9.00-$11.00
Q2 aircraft fuel expense rose $2.3 billion, or 84%; company expects to recover 80%-90% of the increase in Q3 and 100% by Q4
Ending available liquidity of $19.6 billion; total debt and lease obligations of $26.5 billion at quarter end
Union Bankshares reported second-quarter 2026 net income of $2.9 million, or $0.61 per share, up from $2.4 million, or $0.53 per share, a year earlier. Six-month net income was $5.9 million, or $1.26 per share, compared with $4.9 million, or $1.08 per share, in the same period of 2025. The board also declared a $0.36 quarterly dividend, and the press release describes a leadership transition in which David S. Silverman is moving from chief executive to chair.
Q2 2026 net income $2.9 million, or $0.61 per share, versus $2.4 million, or $0.53 per share, in Q2 2025
Six months ended June 30, 2026 net income $5.9 million, or $1.26 per share, versus $4.9 million, or $1.08 per share
Quarterly cash dividend of $0.36 per share, payable August 6, 2026 to holders of record as of July 27, 2026
Jeffrey F. Weidley is president and CEO; David S. Silverman is transitioning from CEO to Chair of the Board
Sprout Social said its board approved a workforce reduction of about 20%, or about 260 employees, on July 8, 2026, and began notifying affected employees on July 15. The company estimates pre-tax restructuring charges of $18.0 million to $20.0 million, mostly severance, with substantially all recognized in the third quarter of 2026. It also said preliminary results for the quarter ended June 30, 2026 are expected at the high end of its outlook ranges for revenue, non-GAAP operating income and non-GAAP net income per share, with full results due August 6, 2026.
Workforce reduction of about 20%, or about 260 employees, approved July 8, 2026; notifications began July 15, 2026
Estimated pre-tax restructuring charges of $18.0 million to $20.0 million, mainly cash severance and benefits, with substantially all recognized in Q3 2026
Preliminary Q2 2026 results expected at the high end of outlook ranges for revenue, non-GAAP operating income and non-GAAP EPS; full results due August 6, 2026 after market close
Veradermics said topline results from its open-label Phase 2 Study 207 showed increases in hair count and patient-reported improvement in women with mild-to-moderate pattern hair loss after six months of oral VDPHL01 treatment. The company said the results support its registration-directed Phase 2/3 Study 306 in women, with topline data expected in the first half of 2027. The filing contains no financial results, and the study was open-label.
Study 207 enrolled 28 adult female participants; women on VDPHL01 4.5 mg once daily or twice daily showed mean non-vellus hair count increases of 22.7 and 23.3 hairs/cm² at Month 6.
88.9% (once daily) and 90.0% (twice daily) of women rated improved or much improved on the AAIRS at Month 6.
No treatment-related serious adverse events were reported; the most common adverse events were hypertrichosis and peripheral edema.
Topline results from Phase 2/3 Study 306 in women are anticipated in the first half of 2027.
Morgan Stanley reported second-quarter 2026 net revenues of $21.3 billion, up from $16.8 billion a year earlier, and diluted EPS of $3.46 versus $2.13. The board also reauthorized a share repurchase program of up to $20 billion and raised the quarterly dividend by 15 cents to $1.15 per share, which matters to shareholders because it signals both higher earnings and expanded capital return.
Net income applicable to Morgan Stanley was $5.6 billion, or $3.46 per diluted share, versus $3.5 billion, or $2.13, a year ago.
The board reauthorized a multi-year common stock repurchase program of up to $20 billion, starting in the third quarter of 2026, with no set expiration date.
The quarterly dividend was raised to $1.15 per share, payable August 14, 2026, to shareholders of record on July 31, 2026.
Johnson & Johnson reported second-quarter 2026 reported sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, up 4.7%, while GAAP diluted EPS was $2.27, down 0.9%. The company raised its 2026 adjusted EPS guidance by $0.13 to a midpoint of $11.68, which signals stronger expected profit for shareholders this year.
Q2 2026 reported sales were $25.3 billion, up 6.6% from $23.7 billion a year earlier.
GAAP diluted EPS was $2.27 versus $2.29 in Q2 2025; net earnings were $5.5 billion, down 0.1%.
Adjusted diluted EPS was $2.90 versus $2.77, up 4.7%.
2026 adjusted EPS guidance midpoint rose to $11.68, up $0.13, with estimated reported sales midpoint of $101.1 billion.
Conagra reported a fourth-quarter fiscal 2026 net loss of $1.6 billion, or $3.37 per diluted share, driven by $2.0 billion of non-cash goodwill and brand impairment charges, while adjusted EPS was $0.47. The board approved a quarterly dividend of $0.175 per share, an annualized rate of $0.70, and the company gave fiscal 2027 adjusted EPS guidance of $1.40 to $1.50, with new CEO John Brase citing margin restoration as a priority.
Q4 reported net sales rose 3.6% to $2.9 billion, but organic net sales were approximately flat
Full-year fiscal 2026 diluted loss was $4.00 per share; adjusted EPS was $1.72
Fiscal 2027 guidance: organic net sales down 3% to 1%, adjusted operating margin 10.0% to 10.5%, adjusted EPS $1.40 to $1.50
Quarterly dividend of $0.175 per share, payable September 2, 2026, to holders of record July 30, 2026
BlackRock reported second quarter 2026 results, with diluted EPS of $12.19, up 20% from $10.19 a year earlier, and $13.91 as adjusted, up 15%. Revenue rose 31% to $7.08 billion and operating income rose 42% to $2.46 billion, and the company raised its planned quarterly share repurchases to $550 million, which matters to shareholders because it signals a larger return of capital.
Q2 2026 revenue was $7,084 million, up from $5,423 million; operating income was $2,461 million, up from $1,731 million.
Q2 2026 long-term net inflows were $199 billion; total net inflows were $192 billion, and first-half net inflows were $321 billion.
Company repurchased $450 million of shares in the quarter and increased planned quarterly repurchases to $550 million.
Assets under management reached $15.3 trillion at June 30, 2026.
Elevance Health reported second-quarter 2026 operating revenue of $49.8 billion, up 0.8% from a year earlier, while diluted earnings per share fell 13.1% to $6.71 from $7.72. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and its adjusted EPS guidance to at least $27.00, and said it is accelerating targeted investments. For shareholders, the higher outlook comes alongside lower quarterly profit and a higher benefit expense ratio.
Operating revenue was $49.8 billion in the second quarter of 2026, up from $49.4 billion a year earlier.
Diluted EPS was $6.71 versus $7.72 a year earlier; adjusted diluted EPS was $7.45 versus $8.84.
Full-year 2026 diluted EPS guidance was raised to at least $20.10 and adjusted diluted EPS guidance to at least $27.00.
Full-year 2026 operating cash flow guidance was raised to at least $6.0 billion; a $1.72 quarterly dividend is payable September 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.